 He maintained his post as company chairman until Johnson & Johnson acquired Synthes in 2012.During his tenure, Wyss said discussions of new products made up one-third of board meetings.A manager assigned to the Norian project testified before a grand jury that "for somebody who is at his level and his level of success, I would say he [Wyss] has a surprising amount of contact with what's going on."